Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer ...

For decades, the process of drug discovery has been a prolonged, costly, and unpredictable endeavor — an effort that ...

Guardant co-CEO Helmy Eltoukhy says the shift to personalized treatment and earlier diagnosis is here at the WIRED Health ...

Anumana Inc., a leader in AI-powered cardiovascular detection algorithms, today announced the appointment of Kevin Ballinger and Jean-Luc Butel to its Board of Directors. In their roles, Ballinger and ...

AI Nose commercial deployment accelerates in 2026 with dual-engine architecture, industrial expansion, and recurring SaaS revenue modelNew Trusval agreement commits to minimum 600-unit deployment, pos ...

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa ...

Partnership Supports Ainos' 2026 Strategic Focus on Advancing AI Nose Upstream and Accelerating Scent Data Accumulation in Advanced Wafer Fabs HOUSTON, TX / ACCESS Newswire / January 7, 2026 / Ainos, ...

Private rheumatologist Dr Anandita Santosa in Singapore notes how current AI in healthcare priorities practically leave ...

Nearly 1.5 million Americans and nearly 5% of women over the age of 55 have rheumatoid arthritis (RA), an incurable ...

The start-up Function will send practically anyone to a lab for extensive medical testing, no physical required. Is that a ...

Lentz, a leading expert in female longevity, examine how today’s longevity movement remains fundamentally male-coded, and why ...

Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...